Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine

Alexander N. Zakhartchouk; Chetna Sharon; Malathy Satkunarajah; Thierry Auperin; Sathiyanarayanan Viswanathan; George Mutwiri; Martin Petric; Raymond H. See; Robert C. Brunham; B. Brett Finlay; Cheryl Cameron; David J. Kelvin; Alan Cochrane; James M. Rini; Lorne A. Babiuk

doi:10.1016/j.vaccine.2006.06.084

Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine

Alexander N. Zakhartchouk, Chetna Sharon, Malathy Satkunarajah, Thierry Auperin, Sathiyanarayanan Viswanathan, George Mutwiri, Martin Petric, Raymond H. See, Robert C. Brunham, B. Brett Finlay, Cheryl Cameron, David J. Kelvin, Alan Cochrane, James M. Rini, Lorne A. Babiuk

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

71 Citas (Scopus)

Resumen

We studied the immunogenicity of an anti-SARS subunit vaccine comprised of the fragment of the SARS coronavirus (SARS-CoV) spike protein amino acids 318-510 (S318-510) containing the receptor-binding domain. The S protein fragment was purified from the culture supernatant of stably transformed HEK293T cells secreting a tagged version of the protein. The vaccine was given subcutaneously to 129S6/SvEv mice in saline, with alum adjuvant or with alum plus CpG oligodeoxynucleotides (ODN). Mice immunized with the adjuvanted antigen elicited strong antibody and cellular immune responses; furthermore, adding the CpG ODN to the alum resulted in increased IgG2a antibody titers and a higher number of INF-γ-secreting murine splenocytes. Mice vaccinated with S318-510 deglycosylated by PNGase F (dgS318-510) showed a lower neutralizing antibody response but had similar numbers of INF-γ-producing cells in the spleen. This finding suggests that carbohydrate is important for the immunogenicity of the S318-510 protein fragment and provide useful information for designing an effective and safe SARS subunit vaccine.

Idioma original	English
Páginas (desde-hasta)	136-143
Número de páginas	8
Publicación	Vaccine
Volumen	25
N.º	1
DOI	https://doi.org/10.1016/j.vaccine.2006.06.084
Estado	Published - ene. 2 2007
Publicado de forma externa	Sí

Nota bibliográfica

Funding Information:
We would like to thank all members of the SARS Accelerated Vaccine Initiative (SAVI) for their dedication and commitment towards this rapid response initiative. We thank the Province of British Columbia, Canada, the Michael Smith Foundation for Health Research and the Protein Engineering Network of Centres of Excellence for funding this project. In addition, we thank the Canadian Institutes of Health Research Strategic Training Program for fellowships to T.A. and C.S. We would like to thank Mr. Barry Carroll and Dr. Igor Moshynskyy for help in work with animals and Mr. Ponn Benjamin for help in setting up the immunological assays. Dr. L.A. Babiuk is a holder of a Canada Research Chair in Vaccinology and Biotechnology. Published as Vaccine and Infectious Disease Organization Series no. 439.

ASJC Scopus Subject Areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.vaccine.2006.06.084

Otros archivos y enlaces

Citar esto

Zakhartchouk, A. N., Sharon, C., Satkunarajah, M., Auperin, T., Viswanathan, S., Mutwiri, G., Petric, M., See, R. H., Brunham, R. C., Finlay, B. B., Cameron, C., Kelvin, D. J., Cochrane, A., Rini, J. M., & Babiuk, L. A. (2007). Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine. Vaccine, 25(1), 136-143. https://doi.org/10.1016/j.vaccine.2006.06.084

Zakhartchouk, AN, Sharon, C, Satkunarajah, M, Auperin, T, Viswanathan, S, Mutwiri, G, Petric, M, See, RH, Brunham, RC, Finlay, BB, Cameron, C, Kelvin, DJ, Cochrane, A, Rini, JM & Babiuk, LA 2007, 'Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine', Vaccine, vol. 25, n.º 1, pp. 136-143. https://doi.org/10.1016/j.vaccine.2006.06.084

@article{1f282351a1724bd3bd7e439d43b6903f,

title = "Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine",

abstract = "We studied the immunogenicity of an anti-SARS subunit vaccine comprised of the fragment of the SARS coronavirus (SARS-CoV) spike protein amino acids 318-510 (S318-510) containing the receptor-binding domain. The S protein fragment was purified from the culture supernatant of stably transformed HEK293T cells secreting a tagged version of the protein. The vaccine was given subcutaneously to 129S6/SvEv mice in saline, with alum adjuvant or with alum plus CpG oligodeoxynucleotides (ODN). Mice immunized with the adjuvanted antigen elicited strong antibody and cellular immune responses; furthermore, adding the CpG ODN to the alum resulted in increased IgG2a antibody titers and a higher number of INF-γ-secreting murine splenocytes. Mice vaccinated with S318-510 deglycosylated by PNGase F (dgS318-510) showed a lower neutralizing antibody response but had similar numbers of INF-γ-producing cells in the spleen. This finding suggests that carbohydrate is important for the immunogenicity of the S318-510 protein fragment and provide useful information for designing an effective and safe SARS subunit vaccine.",

author = "Zakhartchouk, {Alexander N.} and Chetna Sharon and Malathy Satkunarajah and Thierry Auperin and Sathiyanarayanan Viswanathan and George Mutwiri and Martin Petric and See, {Raymond H.} and Brunham, {Robert C.} and Finlay, {B. Brett} and Cheryl Cameron and Kelvin, {David J.} and Alan Cochrane and Rini, {James M.} and Babiuk, {Lorne A.}",

note = "Funding Information: We would like to thank all members of the SARS Accelerated Vaccine Initiative (SAVI) for their dedication and commitment towards this rapid response initiative. We thank the Province of British Columbia, Canada, the Michael Smith Foundation for Health Research and the Protein Engineering Network of Centres of Excellence for funding this project. In addition, we thank the Canadian Institutes of Health Research Strategic Training Program for fellowships to T.A. and C.S. We would like to thank Mr. Barry Carroll and Dr. Igor Moshynskyy for help in work with animals and Mr. Ponn Benjamin for help in setting up the immunological assays. Dr. L.A. Babiuk is a holder of a Canada Research Chair in Vaccinology and Biotechnology. Published as Vaccine and Infectious Disease Organization Series no. 439.",

year = "2007",

month = jan,

day = "2",

doi = "10.1016/j.vaccine.2006.06.084",

language = "English",

volume = "25",

pages = "136--143",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice

T2 - Implications for a subunit vaccine

AU - Zakhartchouk, Alexander N.

AU - Sharon, Chetna

AU - Satkunarajah, Malathy

AU - Auperin, Thierry

AU - Viswanathan, Sathiyanarayanan

AU - Mutwiri, George

AU - Petric, Martin

AU - See, Raymond H.

AU - Brunham, Robert C.

AU - Finlay, B. Brett

AU - Cameron, Cheryl

AU - Kelvin, David J.

AU - Cochrane, Alan

AU - Rini, James M.

AU - Babiuk, Lorne A.

N1 - Funding Information: We would like to thank all members of the SARS Accelerated Vaccine Initiative (SAVI) for their dedication and commitment towards this rapid response initiative. We thank the Province of British Columbia, Canada, the Michael Smith Foundation for Health Research and the Protein Engineering Network of Centres of Excellence for funding this project. In addition, we thank the Canadian Institutes of Health Research Strategic Training Program for fellowships to T.A. and C.S. We would like to thank Mr. Barry Carroll and Dr. Igor Moshynskyy for help in work with animals and Mr. Ponn Benjamin for help in setting up the immunological assays. Dr. L.A. Babiuk is a holder of a Canada Research Chair in Vaccinology and Biotechnology. Published as Vaccine and Infectious Disease Organization Series no. 439.

PY - 2007/1/2

Y1 - 2007/1/2

N2 - We studied the immunogenicity of an anti-SARS subunit vaccine comprised of the fragment of the SARS coronavirus (SARS-CoV) spike protein amino acids 318-510 (S318-510) containing the receptor-binding domain. The S protein fragment was purified from the culture supernatant of stably transformed HEK293T cells secreting a tagged version of the protein. The vaccine was given subcutaneously to 129S6/SvEv mice in saline, with alum adjuvant or with alum plus CpG oligodeoxynucleotides (ODN). Mice immunized with the adjuvanted antigen elicited strong antibody and cellular immune responses; furthermore, adding the CpG ODN to the alum resulted in increased IgG2a antibody titers and a higher number of INF-γ-secreting murine splenocytes. Mice vaccinated with S318-510 deglycosylated by PNGase F (dgS318-510) showed a lower neutralizing antibody response but had similar numbers of INF-γ-producing cells in the spleen. This finding suggests that carbohydrate is important for the immunogenicity of the S318-510 protein fragment and provide useful information for designing an effective and safe SARS subunit vaccine.

AB - We studied the immunogenicity of an anti-SARS subunit vaccine comprised of the fragment of the SARS coronavirus (SARS-CoV) spike protein amino acids 318-510 (S318-510) containing the receptor-binding domain. The S protein fragment was purified from the culture supernatant of stably transformed HEK293T cells secreting a tagged version of the protein. The vaccine was given subcutaneously to 129S6/SvEv mice in saline, with alum adjuvant or with alum plus CpG oligodeoxynucleotides (ODN). Mice immunized with the adjuvanted antigen elicited strong antibody and cellular immune responses; furthermore, adding the CpG ODN to the alum resulted in increased IgG2a antibody titers and a higher number of INF-γ-secreting murine splenocytes. Mice vaccinated with S318-510 deglycosylated by PNGase F (dgS318-510) showed a lower neutralizing antibody response but had similar numbers of INF-γ-producing cells in the spleen. This finding suggests that carbohydrate is important for the immunogenicity of the S318-510 protein fragment and provide useful information for designing an effective and safe SARS subunit vaccine.

UR - http://www.scopus.com/inward/record.url?scp=33845194637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845194637&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.06.084

DO - 10.1016/j.vaccine.2006.06.084

M3 - Article

C2 - 16919855

AN - SCOPUS:33845194637

SN - 0264-410X

VL - 25

SP - 136

EP - 143

JO - Vaccine

JF - Vaccine

IS - 1

ER -

Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto